C. Darton, Thomas Jones, Claire J. Blohmke, Christoph S. Waddington, Claire Zhou, Liqing Peters, Anna Haworth, Kathryn Sie, Rebecca Green, Christopher A. Jeppesen, Catherine A. Moore, Maria Thompson, Ben A. V. John, Tessa A. Kingsley, Robert Yu, Ly-Mee Voysey, Merryn Hindle, Zoe Lockhart, Stephen B. Sztein, Marcelo Dougan, Gordon Angus, Brian M. Levine, Myron Pollard, Andrew J. Summary of vaccine efficacy endpoints and severity measures reached during the 14-day challenge period. <p>Summary of vaccine efficacy endpoints and severity measures reached during the 14-day challenge period.</p> Typhoid Vaccines M 01ZH;dose;Ty 21a Background Typhoid;Salmonella enterica serovar Typhi;Trial registration ClinicalTrials.gov;Ty 21a Retrospective multivariable analyses;1 log increase;10 4 CFU S;14 day challenge period;Typhi Quailes strain;vaccine;placebo;M 01ZH;Measure Vaccine Efficacy;CI;efficacy;VE;Human Challenge Model;participant;UK;typhoid;NCT 2016-08-17
    https://plos.figshare.com/articles/dataset/Summary_of_vaccine_efficacy_endpoints_and_severity_measures_reached_during_the_14-day_challenge_period_/3653979
10.1371/journal.pntd.0004926.t002